Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0111
Virpax Pharmaceuticals Inc Aktie (VRPX) Neueste Nachrichten
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax reports positive study results for pain management drug - MSN
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Reports on Progress of Envelta™ - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Star TribuneVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals names new board director - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug - Stock Titan
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Stock Titan
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
3 Penny Stocks to Watch Now, 7/23/24 - Nasdaq
Maxim Group Upgrades Virpax Pharmaceuticals (VRPX) - Nasdaq
Virpax Pharma rises as pain medication shows promise in animal study - TradingView
Virpax overhauls its board as a condition of $2.5M loan deal; stock price doubles - The Business Journals
Virpax Pharmaceuticals faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Virpax Pharmaceuticals Reports Increased Losses Amid Promising Developments - MyChesCo
Virpax Pharmaceuticals Reports 2023 Year-End Results - The AI Journal
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions - MyChesCo
0.11%
Kapitalisierung:
|
Volumen (24h):